Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7371) 7371
Newspaper Article (161) 161
Newsletter (159) 159
Book Chapter (135) 135
Book / eBook (13) 13
Magazine Article (13) 13
Dissertation (9) 9
Conference Proceeding (7) 7
Publication (3) 3
Trade Publication Article (3) 3
Report (2) 2
Transcript (2) 2
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
multiple sclerosis (6871) 6871
science & technology (5999) 5999
life sciences & biomedicine (5615) 5615
humans (5550) 5550
neurosciences & neurology (4310) 4310
female (4047) 4047
male (3824) 3824
adult (3792) 3792
clinical neurology (3651) 3651
middle aged (3025) 3025
neurosciences (3023) 3023
neurology (2876) 2876
magnetic resonance imaging (2836) 2836
biological and medical sciences (1643) 1643
medical sciences (1636) 1636
multiple sclerosis and variants. guillain barré syndrome and other inflammatory polyneuropathies. leukoencephalitis (1271) 1271
multiple sclerosis - pathology (1263) 1263
brain - pathology (1136) 1136
young adult (1004) 1004
disease progression (992) 992
research (977) 977
multiple sclerosis - diagnosis (961) 961
patients (929) 929
adolescent (863) 863
neuroimaging (853) 853
care and treatment (796) 796
aged (786) 786
multiple sclerosis - physiopathology (752) 752
nuclear magnetic resonance--nmr (743) 743
diagnosis (739) 739
magnetic resonance imaging - methods (722) 722
disability evaluation (709) 709
nervous system (701) 701
medicine & public health (674) 674
multiple sclerosis - complications (637) 637
multiple sclerosis - drug therapy (619) 619
radiology, nuclear medicine & medical imaging (616) 616
brain (615) 615
immunology (597) 597
multiple sclerosis - diagnostic imaging (580) 580
mri (573) 573
multiple sclerosis, relapsing-remitting - drug therapy (554) 554
studies (551) 551
risk factors (548) 548
medical research (545) 545
treatment outcome (538) 538
medicine (532) 532
multiple sclerosis, relapsing-remitting - pathology (529) 529
development and progression (527) 527
research article (523) 523
atrophy (505) 505
inflammation (477) 477
neuroradiology (468) 468
analysis (462) 462
usage (459) 459
case-control studies (458) 458
follow-up studies (455) 455
degenerative and inherited degenerative diseases of the nervous system. leukodystrophies. prion diseases (452) 452
retrospective studies (443) 443
severity of illness index (442) 442
biomarkers (436) 436
psychiatry (428) 428
medicine, experimental (418) 418
brain - diagnostic imaging (406) 406
cerebrospinal fluid (402) 402
health aspects (402) 402
multiple sclerosis - immunology (401) 401
demyelination (397) 397
interferon (391) 391
animals (389) 389
disease (385) 385
science & technology - other topics (383) 383
clinical trials (379) 379
central nervous system (377) 377
prognosis (377) 377
autoimmune diseases (376) 376
multidisciplinary sciences (376) 376
abridged index medicus (364) 364
drug therapy (364) 364
multiple sclerosis - epidemiology (363) 363
cognitive ability (362) 362
multiple sclerosis, relapsing-remitting - diagnostic imaging (362) 362
recurrence (355) 355
neuropsychological tests (354) 354
multiple sclerosis, relapsing-remitting - physiopathology (351) 351
science (350) 350
multiple sclerosis - therapy (337) 337
spinal cord (324) 324
neurodegeneration (316) 316
prospective studies (313) 313
time factors (312) 312
review (311) 311
neurology. diseases of the nervous system (309) 309
longitudinal studies (308) 308
interferon-beta - therapeutic use (307) 307
lesions (300) 300
cognition (295) 295
cohort studies (293) 293
multiple sclerosis, relapsing-remitting - diagnosis (290) 290
medical imaging (282) 282
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Faculty of Information - Cataloguing (1) 1
OISE - Theses (1) 1
UTL at Downsview - May be requested (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7821) 7821
Spanish (22) 22
German (20) 20
French (17) 17
Portuguese (15) 15
Russian (10) 10
Turkish (7) 7
Hungarian (4) 4
Italian (3) 3
Norwegian (3) 3
Polish (3) 3
Danish (2) 2
Japanese (2) 2
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
by Kappos, Ludwig and De Stefano, Nicola and Freedman, Mark S and Cree, Bruce AC and Radue, Ernst-Wilhelm and Sprenger, Till and Sormani, Maria Pia and Smith, Terence and Häring, Dieter A and Piani Meier, Daniela and Tomic, Davorka
Multiple sclerosis, ISSN 1352-4585, 9/2016, Volume 22, Issue 10, pp. 1297 - 1305
Atrophy | NEDA | brain | fingolimod | multiple sclerosis | Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Brain - diagnostic imaging | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Organ Size | Male | Treatment Outcome | Young Adult | Magnetic Resonance Imaging | Clinical Trials, Phase III as Topic | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Adolescent | Brain - pathology | Adult | Female | Fingolimod Hydrochloride - therapeutic use | Multiple sclerosis | Index Medicus | Original Research Papers
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing–remitting multiple sclerosis
by Unterrainer, Marcus and Mahler, C and Vomacka, L and Lindner, S and Havla, J and Brendel, M and Böning, G and Ertl-Wagner, B and Kümpfel, T and Milenkovic, V.M and Rupprecht, R and Kerschensteiner, M and Bartenstein, P and Albert, Nathalie L
European journal of nuclear medicine and molecular imaging, ISSN 1619-7070, 07/2018, Volume 45, Issue 8, pp. 1423 - 1431
Neuroinflammation | TSPO | Multiple sclerosis | F]GE-180 | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Prospective Studies | Humans | Middle Aged | Male | Positron-Emission Tomography | Multiple Sclerosis | Young Adult | Carbazoles | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Receptors, GABA - metabolism | Adult | Female | Aged | Neuroimaging | Brain | Visual cortex | Nuclear magnetic resonance--NMR | Macrophages | Cell activation | Cortex (frontal) | Tomography | Lesions | Cortex (temporal) | Abnormalities | Feasibility studies | Positron emission | Inspection | Fluorine isotopes | Inflammation | Binders | Patients | Microglia | Magnetic resonance imaging | Genotyping | Monoclonal antibodies | Affinity | Positron emission tomography
Journal Article
Details down arrow
3. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study
by Kappos, Ludwig and Li, David K. B and Stuve, Olaf and Hartung, Hans-Peter and Freedman, Mark S and Hemmer, Bernhard and Rieckmann, Peter and Montalban, Xavier and Ziemssen, Tjalf and Hunter, Brian and Arnould, Sophie and Wallstrom, Erik and Selmaj, Krzysztof
JAMA neurology, ISSN 2168-6149, 09/2016, Volume 73, Issue 9, pp. 1089 - 1098
Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Severity of Illness Index | Double-Blind Method | Follow-Up Studies | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Male | Treatment Outcome | Dose-Response Relationship, Drug | Magnetic Resonance Imaging | Azetidines - therapeutic use | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Benzyl Compounds - therapeutic use | Adult | Female | Retrospective Studies
Journal Article
Details down arrow
4. Full Text Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis
by Rossi, Silvia and Studer, Valeria and Motta, Caterina and Polidoro, Serena and Perugini, Jacopo and Macchiarulo, Giulia and Giovannetti, Ambra Mara and Pareja-Gutierrez, Lorena and Calò, Andrea and Colonna, Isabella and Furlan, Roberto and Martino, Gianvito and Centonze, Diego
Neurology, ISSN 0028-3878, 08/2017, Volume 89, Issue 13, pp. 1338 - 1347
Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Multivariate Analysis | Brain - diagnostic imaging | Follow-Up Studies | Humans | Male | Anxiety - drug therapy | Depression - drug therapy | Psychiatric Status Rating Scales | Interleukin-2 - cerebrospinal fluid | Anxiety - diagnostic imaging | Anti-Inflammatory Agents - therapeutic use | Anxiety - complications | Adult | Depression - complications | Female | Disability Evaluation | Multiple Sclerosis, Relapsing-Remitting - immunology | Comorbidity | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Interleukin-1beta - cerebrospinal fluid | Tumor Necrosis Factor-alpha - cerebrospinal fluid | Linear Models | Logistic Models | Anxiety - immunology | Magnetic Resonance Imaging | Multiple Sclerosis, Relapsing-Remitting - psychology | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Depression - diagnostic imaging | Brain - immunology | Depression - immunology | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Diffusion tensor imaging based network analysis detects alterations of neuroconnectivity in patients with clinically early relapsing‐remitting multiple sclerosis
by Li, Yang and Jewells, Valerie and Kim, Minjeong and Chen, Yasheng and Moon, Andrew and Armao, Diane and Troiani, Luigi and Markovic‐Plese, Silva and Lin, Weili and Shen, Dinggang
Human brain mapping, ISSN 1065-9471, 12/2013, Volume 34, Issue 12, pp. 3376 - 3391
diffusion tensor imaging | network analysis | indirect connections | multiple sclerosis | Multiple sclerosis | Indirect connections | Network analysis | Diffusion tensor imaging | Neuroimaging | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Neurology | Radiodiagnosis. Nmr imagery. Nmr spectrometry | Investigative techniques, diagnostic techniques (general aspects) | Nervous system involvement in other diseases. Miscellaneous | Biological and medical sciences | Nervous system | Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis | Medical sciences | Multiple Sclerosis, Relapsing-Remitting - pathology | Humans | Middle Aged | Probability | Male | Multiple Sclerosis, Relapsing-Remitting - physiopathology | Case-Control Studies | Walking - physiology | Image Processing, Computer-Assisted | Nerve Fibers, Myelinated - pathology | Diffusion Magnetic Resonance Imaging | Brain - pathology | Brain Mapping | Adult | Female | Care and treatment | Relapse | Diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
by Havrdova, E and Giovannoni, G and Gold, R and Fox, R. J and Kappos, L and Phillips, J. Theodore and Okwuokenye, M and Marantz, J. L
European journal of neurology, ISSN 1351-5101, 05/2017, Volume 24, Issue 5, pp. 726 - 733
magnetic resonance imaging | no evidence of disease activity | relapsing–remitting multiple sclerosis | dimethyl fumarate | disease monitoring | disability progression | clinical relapse | Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Glatiramer Acetate - pharmacology | Recurrence | Glatiramer Acetate - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Magnetic Resonance Imaging - methods | Male | Treatment Outcome | Disease Progression | Dimethyl Fumarate - pharmacology | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Adult | Female | Delayed-Action Preparations | Dimethyl Fumarate - administration & dosage | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - administration & dosage | Multiple sclerosis | Interferon | Nuclear magnetic resonance--NMR | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
by Hauser, Stephen L and Waubant, Emmanuelle and Arnold, Douglas L and Vollmer, Timothy and Antel, Jack and Fox, Robert J and Bar-Or, Amit and Panzara, Michael and Sarkar, Neena and Agarwal, Sunil and Langer-Gould, Annette and Smith, Craig H and HERMES Trial Grp and HERMES Trial Group
The New England journal of medicine, ISSN 0028-4793, 02/2008, Volume 358, Issue 7, pp. 676 - 688
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Gadolinium | Male | Immunoglobulins - blood | Adult | Female | B-Lymphocytes - metabolism | Multiple Sclerosis, Relapsing-Remitting - pathology | Antibodies, Monoclonal, Murine-Derived | Antigens, CD20 | Multiple Sclerosis, Relapsing-Remitting - immunology | Double-Blind Method | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Antibodies, Monoclonal - pharmacology | Rituximab | Remission Induction | B-Lymphocytes - drug effects | Magnetic Resonance Imaging | B-Lymphocytes - immunology | Adolescent | Brain - pathology | Immunologic Factors - adverse effects | Infusions, Intravenous | Immunologic Factors - pharmacology | Immunologic Factors - therapeutic use | Causes of | B cells | Drug therapy | Health aspects | Sclerosis | Disability | Multiple sclerosis | Cytokines | Lymphocytes | Patients | Immune system | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis
by Novakova, Lenka and Axelsson, Markus and Khademi, Mohsen and Zetterberg, Henrik and Blennow, Kaj and Malmeström, Clas and Piehl, Fredrik and Olsson, Tomas and Lycke, Jan and Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap and Institute of Neuroscience and Physiology and Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi and Göteborgs universitet and Gothenburg University and Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry and Sahlgrenska Academy and Sahlgrenska akademin and Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Institutionen för neurovetenskap och fysiologi
Journal of neurochemistry, ISSN 0022-3042, 04/2017, Volume 141, Issue 2, pp. 296 - 304
disease activity | biomarkers | multiple sclerosis | cerebrospinal fluid | treatment efficacy | Biochemistry & Molecular Biology | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Male | Treatment Outcome | Multiple Sclerosis, Relapsing-Remitting - diagnosis | Disease Progression | Glial Fibrillary Acidic Protein - cerebrospinal fluid | Neurofilament Proteins - cerebrospinal fluid | Young Adult | Natalizumab - therapeutic use | Adolescent | Adult | Female | Biomarkers - cerebrospinal fluid | Multiple Sclerosis, Relapsing-Remitting - cerebrospinal fluid | Chemokine CXCL13 - cerebrospinal fluid | Immunologic Factors - therapeutic use | Multiple sclerosis | Interferon | Diagnostic imaging | Biological response modifiers | Biological markers | Neurochemistry | Biomarkers | Drug therapy | Index Medicus | Neurovetenskaper | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Multimodal quantitative MRI assessment of cortical damage in relapsing‐remitting multiple sclerosis
by Gracien, René‐Maxime and Jurcoane, Alina and Wagner, Marlies and Reitz, Sarah C and Mayer, Christoph and Volz, Steffen and Hof, Stephanie‐Michelle and Fleischer, Vinzenz and Droby, Amgad and Steinmetz, Helmuth and Groppa, Sergiu and Hattingen, Elke and Deichmann, Ralf and Klein, Johannes C
Journal of magnetic resonance imaging, ISSN 1053-1807, 12/2016, Volume 44, Issue 6, pp. 1600 - 1607
quantitative MRI | MTR | cortical gray matter | T1 relaxation time | proton density | multiple sclerosis | relaxation time | Life Sciences & Biomedicine | Radiology, Nuclear Medicine & Medical Imaging | Science & Technology | Multiple Sclerosis, Relapsing-Remitting - pathology | Reproducibility of Results | Humans | Image Interpretation, Computer-Assisted - methods | Cerebral Cortex - pathology | Magnetic Resonance Imaging - methods | Male | Cerebral Cortex - diagnostic imaging | Gray Matter - diagnostic imaging | Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging | Sensitivity and Specificity | Gray Matter - pathology | Multimodal Imaging - methods | Adult | Female | Image Enhancement - methods | Magnetization | Magnetic resonance imaging | Multiple sclerosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights